Dunn SE - Search Results

1

Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival.

Troussard AA, McDonald PC, Wederell ED, Mawji NM, Filipenko NR, Gelmon KA, Kucab JE, Dunn SE, Emerman JT, Bally MB, Dedhar S. Troussard AA, et al. Among authors: dunn se. Cancer Res. 2006 Jan 1;66(1):393-403. doi: 10.1158/0008-5472.CAN-05-2304. Cancer Res. 2006. PMID: 16397254 Free article.

2

Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin.

Nielsen TO, Andrews HN, Cheang M, Kucab JE, Hsu FD, Ragaz J, Gilks CB, Makretsov N, Bajdik CD, Brookes C, Neckers LM, Evdokimova V, Huntsman DG, Dunn SE. Nielsen TO, et al. Among authors: dunn se. Cancer Res. 2004 Jan 1;64(1):286-91. doi: 10.1158/0008-5472.can-03-1242. Cancer Res. 2004. PMID: 14729636

3

Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma.

Makretsov NA, Huntsman DG, Nielsen TO, Yorida E, Peacock M, Cheang MC, Dunn SE, Hayes M, van de Rijn M, Bajdik C, Gilks CB. Makretsov NA, et al. Among authors: dunn se. Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6143-51. doi: 10.1158/1078-0432.CCR-04-0429. Clin Cancer Res. 2004. PMID: 15448001

4

Role of IGF-1R in mediating breast cancer invasion and metastasis.

Kucab JE, Dunn SE. Kucab JE, et al. Among authors: dunn se. Breast Dis. 2003;17:41-7. doi: 10.3233/bd-2003-17105. Breast Dis. 2003. PMID: 15687676

5

Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells.

Sutherland BW, Kucab J, Wu J, Lee C, Cheang MC, Yorida E, Turbin D, Dedhar S, Nelson C, Pollak M, Leighton Grimes H, Miller K, Badve S, Huntsman D, Blake-Gilks C, Chen M, Pallen CJ, Dunn SE. Sutherland BW, et al. Among authors: dunn se. Oncogene. 2005 Jun 16;24(26):4281-92. doi: 10.1038/sj.onc.1208590. Oncogene. 2005. PMID: 15806160

6

Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours.

Kucab JE, Lee C, Chen CS, Zhu J, Gilks CB, Cheang M, Huntsman D, Yorida E, Emerman J, Pollak M, Dunn SE. Kucab JE, et al. Among authors: dunn se. Breast Cancer Res. 2005;7(5):R796-807. doi: 10.1186/bcr1294. Epub 2005 Aug 1. Breast Cancer Res. 2005. PMID: 16168126 Free PMC article.

7

Celecoxib inhibits urokinase-type plasminogen activator (uPA) production in MDA-MB-231 breast cancer cells.

Andrews HN, Habibi G, Kucab JE, Dunn SE. Andrews HN, et al. Among authors: dunn se. Breast Cancer Res Treat. 2005 Nov;94(1):47-52. doi: 10.1007/s10549-005-6941-5. Breast Cancer Res Treat. 2005. PMID: 16172791

8

Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2.

Wu J, Lee C, Yokom D, Jiang H, Cheang MC, Yorida E, Turbin D, Berquin IM, Mertens PR, Iftner T, Gilks CB, Dunn SE. Wu J, et al. Among authors: dunn se. Cancer Res. 2006 May 1;66(9):4872-9. doi: 10.1158/0008-5472.CAN-05-3561. Cancer Res. 2006. PMID: 16651443 Free article.

9

Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers.

Waterhouse DN, Gelmon KA, Klasa R, Chi K, Huntsman D, Ramsay E, Wasan E, Edwards L, Tucker C, Zastre J, Wang YZ, Yapp D, Dragowska W, Dunn S, Dedhar S, Bally MB. Waterhouse DN, et al. Curr Cancer Drug Targets. 2006 Sep;6(6):455-89. doi: 10.2174/156800906778194586. Curr Cancer Drug Targets. 2006. PMID: 17017873 Review.

10

The phosphoinositide-dependent kinase-1 inhibitor 2-amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-acetamide (OSU-03012) prevents Y-box binding protein-1 from inducing epidermal growth factor receptor.

To K, Zhao Y, Jiang H, Hu K, Wang M, Wu J, Lee C, Yokom DW, Stratford AL, Klinge U, Mertens PR, Chen CS, Bally M, Yapp D, Dunn SE. To K, et al. Among authors: dunn se. Mol Pharmacol. 2007 Sep;72(3):641-52. doi: 10.1124/mol.107.036111. Epub 2007 Jun 26. Mol Pharmacol. 2007. PMID: 17595327

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

169 results

Search Page